Skip to content
Bending the Curve Trial by Trial
?

Back to Cervical cancer

References: Cervical cancer

103 sources cited on this page. Links open the primary source.

  1. Wellcome Collection library catalogue record: Wertheim E. Die erweiterte abdominale Operation bei Carcinoma colli uteri: auf Grund von 500 Fällen. Berlin: Urban & Schwarzenberg; 1911. 223 pages (the library copy lacks pages 161-223). Language: German. Source
  2. SCHERER WF, SYVERTON JT, GEY GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953;97(5):695-710. PubMedDOI
    CiteLoading…
  3. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44(2):265-72. PubMed
    CiteLoading…
  4. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111-4. PubMedDOI
    CiteLoading…
  5. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154-61. PubMedDOI
    CiteLoading…
  6. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43. PubMedDOI
    CiteLoading…
  7. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17(9):2676-80. PubMedDOI
    CiteLoading…
  8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53. PubMedDOI
    CiteLoading…
  9. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48. PubMedDOI
    CiteLoading…
  10. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284):781-6. PubMedDOI
    CiteLoading…
  11. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20(4):966-72. PubMedDOI
    CiteLoading…
  12. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872-80. PubMedDOI
    CiteLoading…
  13. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113-9. PubMedDOI
    CiteLoading…
  14. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626-33. PubMedDOI
    CiteLoading…
  15. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-101. PubMedDOI
    CiteLoading…
  16. US Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus (news release, 8 June 2006), as reprinted in full by the Immunization Action Coalition, IZ Express issue 604. Source
  17. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27. PubMedDOI
    CiteLoading…
  18. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802-12. PubMedDOI
    CiteLoading…
  19. Lucey BP, Nelson-Rees WA, Hutchins GM. Henrietta Lacks, HeLa cells, and cell culture contamination. Arch Pathol Lab Med. 2009;133(9):1463-7. PubMedDOI
    CiteLoading…
  20. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649-55. PubMedDOI
    CiteLoading…
  21. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;2010(1):CD008285. PubMedDOI
    CiteLoading…
  22. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88. PubMedDOI
    CiteLoading…
  23. Hudson KL, Collins FS. Biospecimen policy: Family matters. Nature. 2013;500(7461):141-2. PubMedDOI
    CiteLoading…
  24. Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, Stütz AM, et al. The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda). 2013;3(8):1213-24. PubMedDOI
    CiteLoading…
  25. FDA. Supplement approval letter, BLA 125085/S-301 (Avastin, bevacizumab), signed 14 August 2014. Source
  26. US Food and Drug Administration, Center for Devices and Radiological Health. Approval order, PMA supplement P100020/S008, cobas HPV Test (Roche Molecular Systems, Inc.), dated April 24, 2014. Source
  27. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32. PubMedDOI
    CiteLoading…
  28. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-43. PubMedDOI
    CiteLoading…
  29. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 2015;33(19):2129-35. PubMedDOI
    CiteLoading…
  30. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-97. PubMedDOI
    CiteLoading…
  31. Beskow LM. Lessons from HeLa Cells: The Ethics and Policy of Biospecimens. Annu Rev Genomics Hum Genet. 2016;17:395-417. PubMedDOI
    CiteLoading…
  32. Swailes AL, Gockley A, Phaëton R, Kesterson JP. The Wertheim hysterectomy: Development, modifications, and impact in the present day. Gynecol Oncol. 2017;145(1):3-8. PubMedDOI
    CiteLoading…
  33. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654-1663. PubMedDOI
    CiteLoading…
  34. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823. PubMedDOI
    CiteLoading…
  35. FDA. Supplement approval letter, BLA 125514/S-034 (Keytruda, pembrolizumab), signed 12 June 2018. Source
  36. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018;36(16):1548-1555. PubMedDOI
    CiteLoading…
  37. Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, et al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med. 2018;379(20):1905-1914. PubMedDOI
    CiteLoading…
  38. Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. JAMA. 2018;320(1):43-52. PubMedDOI
    CiteLoading…
  39. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018;379(20):1895-1904. PubMedDOI
    CiteLoading…
  40. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674-686. PubMedDOI
    CiteLoading…
  41. US Preventive Services Task Force. Cervical Cancer: Screening. Recommendation page; final recommendation statement dated August 21, 2018; page banner read 20 October 2026. Source
  42. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37(17):1470-1478. PubMedDOI
    CiteLoading…
  43. Winer RL, Lin J, Tiro JA, Miglioretti DL, Beatty T, Gao H, et al. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw Open. 2019;2(11):e1914729. PubMedDOI
    CiteLoading…
  44. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575-590. PubMedDOI
    CiteLoading…
  45. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. PubMedDOI
    CiteLoading…
  46. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348. PubMedDOI
    CiteLoading…
  47. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102-131. PubMedDOI
  48. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Publication page, published 17 November 2020. Source
  49. Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518-1529. PubMedDOI
    CiteLoading…
  50. Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609-619. PubMedDOI
    CiteLoading…
  51. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867. PubMedDOI
    CiteLoading…
  52. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. PubMedDOI
    CiteLoading…
  53. FDA. Supplement approval and fulfilment of postmarketing requirements letter, BLA 125514/S-121 and S-122 (Keytruda, pembrolizumab), signed 13 October 2021. Source
  54. FDA. Corrected accelerated approval letter, BLA 761208 (Tivdak, tisotumab vedotin-tftv); effective action date 20 September 2021, corrected letter signed 22 September 2021. Source
  55. Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021;31(10):1317-1325. PubMedDOI
    CiteLoading…
  56. Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056. PubMedDOI
    CiteLoading…
  57. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386(6):544-555. PubMedDOI
    CiteLoading…
  58. Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023;21(12):1224-1233. PubMedDOI
  59. Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nat Med. 2023;29(12):3224-3232. PubMedDOI
    CiteLoading…
  60. Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Int J Gynecol Cancer. 2023;33(5):649-666. PubMedDOI
  61. Drouin E, Classe JM, Hautecoeur P. 125 years of the Wertheim operation. What next?. J Med Life. 2023;16(3):341-343. PubMedDOI
    CiteLoading…
  62. Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, et al. Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994. J Clin Oncol. 2023;41(32):5035-5043. PubMedDOI
    CiteLoading…
  63. Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):468-482. PubMedDOI
    CiteLoading…
  64. Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505-5511. PubMedDOI
    CiteLoading…
  65. Monk BJ, Toita T, Wu X, Vázquez Limón JC, Tarnawski R, Mandai M, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1334-1348. PubMedDOI
    CiteLoading…
  66. Tewari KS, Sill MW, Birrer MJ, Penson RT, Huang H, Moore DH, et al. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023;171:141-150. PubMedDOI
    CiteLoading…
  67. Falcaro M, Soldan K, Ndlela B, Sasieni P. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study. BMJ. 2024;385:e077341. PubMedDOI
    CiteLoading…
  68. FDA. Supplement approval and fulfilment of postmarketing requirement letter, BLA 761208/S-007 (Tivdak, tisotumab vedotin-tftv), signed 29 April 2024. Source
  69. U.S. Food and Drug Administration. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer. Resources for Information, Approved Drugs (announcement text begins 'On January 12, 2024'). Source
  70. U.S. Food and Drug Administration. Supplement approval letter, BLA 125514/S-147, Keytruda (pembrolizumab) in combination with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer. Letter signed electronically 12 January 2024. Source
  71. US Food and Drug Administration, Center for Devices and Radiological Health. Approval order, PMA supplement P100020/S055 (cobas HPV Test) and P190028/S009 (cobas HPV), Roche Molecular Systems, Inc.; decision date 14 May 2024 per the FDA PMA database. Source
  72. US Food and Drug Administration, Center for Devices and Radiological Health. Approval order, PMA supplement P160037/S017 (BD Onclarity HPV Assay), Becton, Dickinson and Company; decision date 14 May 2024 per the FDA PMA database. Source
  73. Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341-1350. PubMedDOI
    CiteLoading…
  74. Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10460):1321-1332. PubMedDOI
    CiteLoading…
  75. McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024;404(10462):1525-1535. PubMedDOI
    CiteLoading…
  76. Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31-43. PubMedDOI
    CiteLoading…
  77. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, et al. Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. N Engl J Med. 2024;390(9):819-829. PubMedDOI
    CiteLoading…
  78. Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, et al. LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. J Clin Oncol. 2024;42(23):2741-2746. PubMedDOI
    CiteLoading…
  79. Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391(1):44-55. PubMedDOI
    CiteLoading…
  80. Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet. 2024;404(10463):1668-1676. PubMedDOI
    CiteLoading…
  81. EMA. Tivdak (tisotumab vedotin): European public assessment report page; opinion adopted 30 January 2025, marketing authorisation issued 28 March 2025 (page read 20 October 2026). Source
  82. EMA. Tivdak (tisotumab vedotin): summary of product characteristics, EU/1/25/1911/001; date of first authorisation 28 March 2025 (EPAR product information, current version read 20 October 2026). Source
  83. U.S. Food and Drug Administration. AVASTIN (bevacizumab) prescribing information, Indications and Usage, via the openFDA drug label API (label version effective 6 January 2025; set id 939b5d1f-9fb2-4499-80ef-0607aa6b114e). Read 20 October 2026. Source
  84. U.S. Food and Drug Administration. TIVDAK (tisotumab vedotin-tftv) prescribing information, Indications and Usage, via the openFDA drug label API (label version effective 20 November 2025; set id c9fe3f32-4219-466e-acb9-3f609b4f4df1). Read 20 October 2026. Source
  85. Kreimer AR, Porras C, Liu D, Hildesheim A, Carvajal LJ, Ocampo R, et al. Noninferiority of One HPV Vaccine Dose to Two Doses. N Engl J Med. 2025;393(24):2421-2433. PubMedDOI
    CiteLoading…
  86. Lorusso D, Colombo N, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Ann Oncol. 2025;36(1):65-75. PubMedDOI
    CiteLoading…
  87. Cancer Research UK. Cervical cancer survival statistics. Health professional page, read from the page HTML. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/survival. Page accessed 20 October 2026; no update date seen. Source
  88. ClinicalTrials.gov. NCT03257267 (EMPOWER-Cervical 1). Registry record, accessed 20 October 2026. NCT03257267
  89. ClinicalTrials.gov. NCT04982237 (COMPASSION-16; sponsor study AK104-303). Registry record, accessed 20 October 2026. NCT04982237
  90. ClinicalTrials.gov. NCT04989647 (CERVANTES). Registry record, API v2, accessed 20 October 2026. NCT04989647
  91. ClinicalTrials.gov. NCT05235516 (AK104-305). Registry record, API v2, accessed 20 October 2026. NCT05235516
  92. ClinicalTrials.gov. NCT05581121 (PAROLA). Registry record, API v2, accessed 20 October 2026. NCT05581121
  93. ClinicalTrials.gov. NCT05764044 (AddChemo). Registry record, API v2, accessed 20 October 2026. NCT05764044
  94. ClinicalTrials.gov. NCT06459687 (socazolimab first-line phase 3). Registry record, API v2, accessed 20 October 2026. NCT06459687
  95. ClinicalTrials.gov. NCT07797153 (JSKN033 phase 3). Registry record, API v2, accessed 20 October 2026. NCT07797153
  96. European Medicines Agency. Keytruda: EPAR overview and product information (indications section). Page accessed 20 October 2026; the page shows several per-document last-updated dates in 2026. Source
  97. EMA. Libtayo (cemiplimab): European public assessment report page; lists monotherapy for recurrent or metastatic cervical cancer progressing on or after platinum-based chemotherapy (page read 20 October 2026). Source
  98. U.S. Food and Drug Administration. KEYTRUDA prescribing information, Indications and Usage, via the openFDA drug label API (label version effective 10 July 2026). Source
  99. FDA. Libtayo (cemiplimab) prescribing information as served by openFDA, set id 4347ae1f-d397-4f18-8b70-03897e1c054a, effective 31 August 2026 (read 20 October 2026). Source
  100. Deutsche Biographie (NDB-online). Wertheim, Ernst (1864-1920), Mediziner, Gynäkologe. Entry with works list; the page shows no publication date (accessed 20 October 2026, so the year recorded is the access year). Source
  101. US Food and Drug Administration. openFDA device PMA API records for P100020 (cobas HPV Test, Roche Molecular Systems, Inc.): original PMA decision and supplements. Queried 20 October 2026. Source
  102. US Food and Drug Administration. openFDA device PMA API records for P160037 (BD Onclarity HPV Assay, Becton, Dickinson and Company): original PMA decision and supplements. Queried 20 October 2026. Source
  103. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Cervical Cancer. Page accessed 20 October 2026; the page displays no update date (its HTTP Last-Modified header reads 22 April 2026). Source